NASDAQ:DNTH Dianthus Therapeutics (DNTH) Stock Price, News & Analysis → Elon Musk’s Next Move Will Disrupt AI Forever (From InvestorPlace) (Ad) Free DNTH Stock Alerts $24.05 -0.24 (-0.99%) (As of 10:51 AM ET) Add Compare Share Share Today's Range$23.69▼$25.2350-Day Range$20.99▼$31.9452-Week Range$6.58▼$33.77Volume19,293 shsAverage Volume141,525 shsMarket Capitalization$705.87 millionP/E RatioN/ADividend YieldN/APrice Target$43.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Dianthus Therapeutics alerts: Email Address Dianthus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside80.9% Upside$43.40 Price TargetShort InterestBearish9.95% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.13Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.92) to ($2.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.86 out of 5 starsMedical Sector840th out of 925 stocksPharmaceutical Preparations Industry398th out of 430 stocks 3.5 Analyst's Opinion Consensus RatingDianthus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDianthus Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Dianthus Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted9.95% of the float of Dianthus Therapeutics has been sold short.Short Interest Ratio / Days to CoverDianthus Therapeutics has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.Change versus previous monthShort interest in Dianthus Therapeutics has recently increased by 12.57%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDianthus Therapeutics does not currently pay a dividend.Dividend GrowthDianthus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DNTH. Previous Next 1.7 News and Social Media Coverage News SentimentDianthus Therapeutics has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Dianthus Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for DNTH on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Dianthus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dianthus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders16.56% of the stock of Dianthus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions47.53% of the stock of Dianthus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dianthus Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Dianthus Therapeutics are expected to decrease in the coming year, from ($1.92) to ($2.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dianthus Therapeutics is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dianthus Therapeutics is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDianthus Therapeutics has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Dianthus Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceElon Musk’s Next Move Will Disrupt AI ForeverA revolutionary venture that is set to get rolled out by May 16. One well-connected Silicon Valley VC has uncovered a way for anybody to claim a stake in "Elon Musk's AI 2.0" with as little as $100.Get all the information here. About Dianthus Therapeutics Stock (NASDAQ:DNTH)Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Read More DNTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DNTH Stock News HeadlinesMay 11, 2024 | americanbankingnews.comDianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up on Analyst UpgradeMay 10, 2024 | investorplace.comDNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024May 13, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. May 9, 2024 | globenewswire.comDianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial ResultsMay 8, 2024 | finance.yahoo.comDianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care ConferenceMay 5, 2024 | americanbankingnews.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 8.1%May 3, 2024 | globenewswire.comDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 18, 2024 | markets.businessinsider.comWhat 5 Analyst Ratings Have To Say About Dianthus TherapeuticsMay 13, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 11, 2024 | globenewswire.comDianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual MeetingApril 5, 2024 | globenewswire.comDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 25, 2024 | finanznachrichten.deDianthus Therapeutics, Inc.: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial ResultsMarch 22, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Xenetic Biosciences (XBIO) and Dianthus Therapeutics (DNTH)March 22, 2024 | finance.yahoo.comDianthus Therapeutics Insiders Added US$2.05m Of Stock To Their HoldingsMarch 21, 2024 | globenewswire.comDianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial ResultsMarch 15, 2024 | finance.yahoo.comEQ Apr 2024 5.000 putMarch 9, 2024 | morningstar.comDianthus Therapeutics Inc DNTHMarch 8, 2024 | finanznachrichten.deDianthus Therapeutics, Inc.: Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 7, 2024 | globenewswire.comDianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 26, 2024 | finanznachrichten.deDianthus Therapeutics, Inc.: Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)February 26, 2024 | globenewswire.comDianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)February 24, 2024 | msn.comDianthus Therapeutics (DNTH) Price Target Increased by 22.22% to 35.53February 23, 2024 | ca.finance.yahoo.comSMCI Jan 2025 1310.000 callFebruary 23, 2024 | finance.yahoo.comSMCI Mar 2024 1070.000 callFebruary 23, 2024 | markets.businessinsider.comDianthus Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 15, 2024 | msn.comStifel starts Dianthus at buy, cites market potential of lead drugFebruary 15, 2024 | benzinga.comDecoding 4 Analyst Evaluations For Dianthus TherapeuticsSee More Headlines Receive DNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dianthus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today5/13/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DNTH CUSIPN/A CIK1690585 Webdianthustx.com Phone857-242-0170FaxN/AEmployees53Year FoundedN/APrice Target and Rating Average Stock Price Target$43.40 High Stock Price Target$51.00 Low Stock Price Target$38.00 Potential Upside/Downside+78.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($5.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-43,560,000.00 Net MarginsN/A Pretax Margin-2,226.78% Return on Equity-20.82% Return on Assets-19.86% Debt Debt-to-Equity RatioN/A Current Ratio42.52 Quick Ratio42.52 Sales & Book Value Annual Sales$2.83 million Price / Sales251.91 Cash FlowN/A Price / Cash FlowN/A Book Value$11.40 per share Price / Book2.13Miscellaneous Outstanding Shares29,350,000Free Float24,489,000Market Cap$712.91 million OptionableNo Data Beta1.77 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Marino Garcia M.B.A. (Age 58)President, CEO, Secretary & Director Mr. Edward G. Carr (Age 55)Chief Accounting Officer Mr. Judson TaylorHead of Technical OperationsDr. Jeffrey Stavenhagen Ph.D.Chief Scientific OfficerMs. Jennifer Davis RuffVP and Head of Investor Relations & Corporate Affairs.Ms. Kristina MaximenkoChief People OfficerMs. Rashieda GluckHead of Clinical Development OperationsMr. Scott Nogi M.B.A.Head of Business OperationsMs. Debra SegalHead of Regulatory AffairsMs. Polly HanffHead of QualityMore ExecutivesKey CompetitorsMineralys TherapeuticsNASDAQ:MLYSWave Life SciencesNASDAQ:WVEAnaptysBioNASDAQ:ANABNurix TherapeuticsNASDAQ:NRIXNuvation BioNYSE:NUVBView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 384,182 shares on 5/10/2024Ownership: 1.833%Acadian Asset Management LLCSold 13,876 shares on 5/10/2024Ownership: 0.014%Atlas Venture Life Science Advisors LLCSold 50,000 shares on 5/6/2024Ownership: 0.637%Hussman Strategic Advisors Inc.Bought 21,000 shares on 5/2/2024Ownership: 0.072%Octagon Capital Advisors LPBought 74,000 shares on 2/15/2024Ownership: 3.738%View All Insider TransactionsView All Institutional Transactions DNTH Stock Analysis - Frequently Asked Questions Should I buy or sell Dianthus Therapeutics stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dianthus Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DNTH shares. View DNTH analyst ratings or view top-rated stocks. What is Dianthus Therapeutics' stock price target for 2024? 5 Wall Street analysts have issued twelve-month price objectives for Dianthus Therapeutics' stock. Their DNTH share price targets range from $38.00 to $51.00. On average, they expect the company's stock price to reach $43.40 in the next year. This suggests a possible upside of 80.9% from the stock's current price. View analysts price targets for DNTH or view top-rated stocks among Wall Street analysts. How have DNTH shares performed in 2024? Dianthus Therapeutics' stock was trading at $10.40 on January 1st, 2024. Since then, DNTH shares have increased by 130.7% and is now trading at $23.99. View the best growth stocks for 2024 here. When is Dianthus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our DNTH earnings forecast. How were Dianthus Therapeutics' earnings last quarter? Dianthus Therapeutics, Inc. (NASDAQ:DNTH) issued its quarterly earnings results on Thursday, March, 21st. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.11) by $0.40. The company earned $0.46 million during the quarter, compared to analyst estimates of $0.73 million. What ETF holds Dianthus Therapeutics' stock? iShares Neuroscience and Healthcare ETF holds 1,001 shares of DNTH stock, representing 0.66% of its portfolio. Who are Dianthus Therapeutics' major shareholders? Dianthus Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (1.83%), Atlas Venture Life Science Advisors LLC (0.64%), Hussman Strategic Advisors Inc. (0.07%), Acadian Asset Management LLC (0.01%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Fairmount Funds Management Llc and Simrat Randhawa. View institutional ownership trends. How do I buy shares of Dianthus Therapeutics? Shares of DNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DNTH) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThis 1 Biotech Stock has been shocking the marketsHuge AlertsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsHow Biden has already won 2024Porter & CompanyBill Clinton Backing Biden Replacement???The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
